Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Genitourinary 1Dermatologic 1

Conditions

Multiple Myeloma 14Lymphoma, Non-Hodgkin 10Carcinoma, Non-Small-Cell Lung 7Breast Neoplasms 7Arthritis, Rheumatoid 7Lymphoma, Large B-Cell, Diffuse 5Lymphoma, B-Cell 5Lymphoma 5Solid Tumors 4Recurrence 4Precursor Cell Lymphoblastic Leukemia-Lymphoma 4Neoplasms 4Melanoma 4Leukemia, Myeloid, Acute 4Leukemia, Lymphocytic, Chronic, B-Cell 4Colorectal Neoplasms 4Ovarian Neoplasms 3Lymphoma, Follicular 3Leukemia 3Hematologic Neoplasms 3Cytokine Release Syndrome 3Burkitt Lymphoma 3Urinary Bladder Neoplasms 2Respiratory Distress Syndrome 2Pancreatic Neoplasms 2Myelodysplastic Syndromes 2Lymphoma, Mantle-Cell 2Fallopian Tube Neoplasms 2Craniopharyngioma 2Carcinoma, Hepatocellular 2

Interventions

Gemcitabine 25Cisplatin 18Carboplatin 10Paclitaxel 9Specimen Handling 6Nivolumab 6Doxorubicin 6Docetaxel 6pembrolizumab 5Magnetic Resonance Spectroscopy 5cabozantinib 4avelumab 4Vinblastine 4Radiotherapy 4Methotrexate 4Fluorouracil 4enfortumab vedotin 3atezolizumab 3aflibercept 3Trastuzumab 3Sunitinib 3Ramucirumab 3Platinum 3Ipilimumab 3Immunoglobulin G 3Disulfides 3CTLA-4 Antigen 3Biopsy 31,2-diaminocyclohexaneplatinum II citrate 3vinflunine 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Urethral Neoplasms × tocilizumab × Clear all
NCT04940299 2026-03-06

Tocilizumab, Ipilimumab, and Nivolumab for the Treatment of Advanced Melanoma, Non-Small Cell Lung Cancer, or Urothelial Carcinoma

M.D. Anderson Cancer Center

Phase 2 Active not recruiting
35 enrolled
DermatologicGenitourinaryThoracic

Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Melanoma, Ureteral Neoplasms, Urethral Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡